Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. - Wikidata - wikimedia - TriplyDB

Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.

Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.

http://www.wikidata.org/entity/Q44291391

about

Endothelin receptor antagonists for pulmonary arterial hypertension Endothelin receptor antagonists for pulmonary arterial hypertension Prostacyclin for pulmonary hypertension in adults Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis Treprostinil for the treatment of pulmonary arterial hypertension In vitro microvessels for the study of angiogenesis and thrombosis.Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials.Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review.Experiences with treprostinil in the treatment of pulmonary arterial hypertension.Cardiac manifestations in systemic sclerosis.Integrated care and optimal management of pulmonary arterial hypertension Prostacyclin analogs stimulate receptor-mediated cAMP synthesis and ATP release from rabbit and human erythrocytes.Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes.Prostanoid therapies in the management of pulmonary arterial hypertension.Emerging drugs in the management of hypertension.Treprostinil for pulmonary hypertension.Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single center Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis.Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years.Pulmonary arterial hypertension: classification, diagnosis and contemporary management.Intra-abdominal bleeding during treprostinil infusion in a patient with pulmonary arterial hypertension.Current therapies for pulmonary arterial hypertension.Updated evidence-based treatment algorithm in pulmonary arterial hypertension.Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.An advanced protocol-driven transition from parenteral prostanoids to inhaled trepostinil in pulmonary arterial hypertension Pharmacokinetic evaluation of continuous intravenous epoprostenol.Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.Treatment of pulmonary arterial hypertension in connective tissue disease.Inhaled treprostinil for the treatment of pulmonary arterial hypertension.Practical considerations for the pharmacotherapy of pulmonary arterial hypertension.Optimal use of treprostinil in pulmonary arterial hypertension: a guide to the correct use of different formulations.Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety.Impact on Survival of Warfarin in Patients with Pulmonary Arterial Hypertension Receiving Subcutaneous Treprostinil.Diagnostic and therapeutic algorithm for pulmonary arterial hypertension.

P2860

Q24200714-41F7FDB0-705A-4C9C-B080-318BC0FC401B Q24240009-872F98CD-2096-40AA-ADF2-8292916BD328 Q24246933-E60A46FC-8662-438E-899C-3BC098016823 Q26772960-AEC7A1A7-A7F4-4402-8610-5E83F466816E Q28281899-46C9FD1F-A1F8-4E3E-99F5-25A84071A9E6 Q30519206-2F467704-37D9-46E9-865E-63E9F3AC4B97 Q33673947-503180C6-C721-411C-A163-B06CF4262924 Q33715766-928F4156-9BB8-492D-BA31-80AEF299238A Q33816571-8ACD0D8F-B369-436B-9FE7-02517A301A89 Q33982476-D84B9D8C-0115-4337-99BE-459C721C17F8 Q34251904-25B3DA3F-2C89-4D35-A852-6418CC2EC92B Q34417785-90BA8B58-4286-4673-8F85-D7A91C6852D3 Q34790785-8EA3FDD8-C031-4C4D-866A-3A441986BD09 Q34985436-905318F1-C44F-487C-ABDC-C17EAA283080 Q35284318-84FDC824-9C12-4752-BC53-3B1968D9C8D5 Q35602652-627D30B7-E476-411A-BF74-B81D8DB62E7F Q35777345-C8A4AD80-9B0E-4986-90CE-CFA711DF5F5C Q35792872-C0FB8EA2-4B8D-46E9-B9D2-073D876593E6 Q35829890-3A08B2F1-C6FD-40A7-B38D-47098EAC720E Q35987352-153FAF19-1CB1-4BE8-8FCF-79CCF3FA2F7A Q36016519-AC7ACD1A-7F0B-448D-B31D-D2ACA1AE0C8C Q36129391-8404B84C-FE41-4D21-9227-23A2391D2406 Q36325779-8B0E76A8-C7A6-4750-A253-FE46C1449236 Q36408727-AAB0CE6B-FCBF-478D-BE77-05D22441C786 Q36651071-A43F4622-D453-4E67-A799-094055DDE081 Q36704611-6B0E4E31-5B7E-4C73-B8B0-5AA3259141B3 Q36834630-ACFD17B3-5F60-45DD-87EB-A6C72D3E7AF6 Q36939543-E61C541C-9C7B-480F-85FC-D6893577A04A Q37069668-C3218A89-F19F-4D14-9479-28C3235E114C Q37139801-9E15A1F1-EC20-497F-82D5-467449B136A7 Q37555352-AF1B99EA-4E5D-4E02-8C92-66C915D61C37 Q37809538-121EE72C-716F-4EA8-9890-46491AB76C5D Q37879213-52305329-DEDF-4923-B37D-F48ABEBA52D8 Q38012530-E90C97C9-6D63-4D4B-8DD0-9712088DB9DE Q38025723-9123ABCE-549C-413A-A4D1-6C78B939F834 Q38027095-65B591A6-D6E8-4D51-A285-F593B649F803 Q38066529-5C8D9A70-2580-48CD-8CB3-CA167C5FBBBF Q38175430-705649F6-AC78-4433-A269-914B2C0779C9 Q38712639-8B9CEE4D-5EF9-4C58-A744-F5660935F39B Q38782951-CB1ECE4B-1214-4A1B-B433-3EC613B0922A

P2860

Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.

http://www.wikidata.org/entity/Q44291391

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Efficacy and safety of trepros ...... rimary pulmonary hypertension.

@en

Efficacy and safety of trepros ...... rimary pulmonary hypertension.

@nl

type

label

Efficacy and safety of trepros ...... rimary pulmonary hypertension.

@en

Efficacy and safety of trepros ...... rimary pulmonary hypertension.

@nl

prefLabel

Efficacy and safety of trepros ...... rimary pulmonary hypertension.

@en

Efficacy and safety of trepros ...... rimary pulmonary hypertension.

@nl

P1433

Q44291391-F0B2EDCA-0091-4CA0-A18C-BC6C702F8B6C

P1476

Q44291391-D62C1FED-8334-4D50-A9A2-F227B5FA5580

P2093

Q44291391-032F4ADC-EF51-4CC1-9065-9F8C86CA3032

Q44291391-23A1B09F-5041-4C74-8216-501203D90C3F

Q44291391-2B024462-E686-4259-90E3-B3E0C8B72564

Q44291391-39CE4F91-2CE4-4182-B1DD-D8A7CD51F9FC

Q44291391-4E9DAA08-A08B-418D-B530-DF7C6DBA779E

Q44291391-921D6B56-817A-4226-804F-9AF9D7D154B7

Q44291391-94B9D454-813E-454C-B9A2-0BBAFB3D271D

Q44291391-B234A02B-7A70-44B7-80D2-6DFB3448A7C5

Q44291391-B8B15FB1-5025-45A2-8B7D-EA3C2F11E6DA

Q44291391-C980E87E-C373-48A1-A6CA-A7FD4FC6AFFE

P304

Q44291391-925A7018-169F-4ECB-91CA-06DC54BD0A63

P31

Q44291391-285C6A5D-95B4-4593-82D0-7938D60FD640

P356

Q44291391-27CF7350-8CED-4F82-BBCF-6441C51673FF

P433

Q44291391-332C98E4-0555-4232-9E4F-199DA723D277

P478

Q44291391-A470CACC-C963-4D6A-99AD-83B083D6F2FF

P577

Q44291391-364B5AFE-5940-4764-8447-BDD092AB3F27

P698

Q44291391-58608E91-B99D-46F1-83D9-87D83B7A3F84

P356

00005344-200302000-00019

P1433

Journal of Cardiovascular Pharmacology

P1476

Efficacy and safety of trepros ...... rimary pulmonary hypertension.

@en

P2093

Adaani Frost

http://www.w3.org/2001/XMLSchema#string

Carl Arneson

http://www.w3.org/2001/XMLSchema#string

David B Badesch

http://www.w3.org/2001/XMLSchema#string

Ivan M Robbins

http://www.w3.org/2001/XMLSchema#string

Jeff Sigman

http://www.w3.org/2001/XMLSchema#string

Lewis J Rubin

http://www.w3.org/2001/XMLSchema#string

Michael D McGoon

http://www.w3.org/2001/XMLSchema#string

Robert C Bourge

http://www.w3.org/2001/XMLSchema#string

Robert Roscigno

http://www.w3.org/2001/XMLSchema#string

Robyn J Barst

http://www.w3.org/2001/XMLSchema#string

P304

293-299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00005344-200302000-00019

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12548091

http://www.w3.org/2001/XMLSchema#string